MS on Anti-CD20 – Influenza Vaccination — SCE Neurology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Inactivated influenza vaccine should be given annually — ideally timed ≥12 weeks after the last ocrelizumab infusion and ≥4 weeks before the next to optimise the antibody response; live vaccines are contraindicated
Inactivated vaccines (including influenza) are safe on ocrelizumab but the antibody response is attenuated. Timing relative to infusion cycles can optimise response. Live vaccines (live attenuated influenza nasal spray, BCG, MMR, varicella) are contraindicated on anti-CD20 therapy. Annual influenza vaccination is recommended for all immunosuppressed patients. A: Inactivated vaccines are safe. C: Live influenza vaccine is contraindicated. D: Vaccination is recommended. E: Multiple vaccines are important.
Reference: ABN MS Guidelines; Green Book; Ocrelizumab SmPC